HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dual Status Rx/OTC Plan B In The Works? Barr Weighs Its Options

This article was originally published in The Tan Sheet

Executive Summary

Barr hinted that it is leaning toward a dual label Rx/OTC approach in seeking FDA approval to switch the Plan B "morning after" pill

You may also be interested in...



FDA “Unable” To Decide On Plan B, Seeks Comment On Dual-Status Drugs

FDA believes additional information on whether a drug can be marketed both Rx and OTC for the same indication is needed before a decision can be reached on Barr Labs' switch application for Plan B

Barr Submits Plan B Response To FDA, Starts 180-Day Review Clock

An FDA decision on OTC availability of Barr Labs' Plan B emergency contraceptive is expected by the end of January

Bad Precedent? Plan B Dual Labeling Could Impact Existing OTCs – NEJM

Dual Rx/OTC labeling for the Plan B emergency contraceptive may have similar implications for medications that are already available over the counter, according to an editorial in the June 3 New England Journal of Medicine

Related Content

Topics

UsernamePublicRestriction

Register

RS128428

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel